Cabaletta Bio, Inc. (CABA)
Develops engineered T cell treatments for autoimmune diseases like lupus and multiple sclerosis.
$2.73+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+89.6%
The outlook
Cabaletta Bio is trading well below its short- and long-term moving averages, sitting roughly midway in its 52-week range. Analyst coverage shows a notably bullish average price target about 390% above the current price, though the stock's neutral overall score reflects mixed sentiment. The price has been flat today against a backdrop of depressed recent momentum.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range49% of the way from its 52-week low to high
Price targetAvg target +390% vs current price
Analyst price target
~12-month · 8 analysts$13.38average target+389.9% vs now
Now $2.73
Low $4.00High $30.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$445.1M
52-wk high
$4.23
52-wk low
$1.26
50-day avg
$3.14
200-day avg
$2.86
Trailing P/E
—